Business
Altimmune is a late clinical-stage biopharma company focused on pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist in development for MASH, alcohol use disorder, and alcohol-associated liver disease.
Altimmune remained a clinical-stage biotech, with FY2025 revenue of $41K, a narrower net loss of $88.1M, and a cluster-buy insider signal.
The read at a glance✓ Audited against SEC data
- Business mix — Pemvidutide-led liver disease pipelineNote
- Revenue — Revenue was $41KNote
- Profitability — Net loss narrowed to $88.1MNote
- Cash — Free cash flow was negative $67.5MNote
- Equity — Equity rose 82.1% to $224.9MOK
- Insiders — 10 buys / 0 sells; cluster buyOK
- Accounting — Altman-Z distress; other scores unavailableWatch
Leadership changes
From Altimmune, Inc.'s own filings, the day they're filed.
- Vipin K. Garg · Chief Executive Officer · departureeff. 2026-01-01
- Jerome Durso · President · appointmenteff. 2025-12-01
- Christophe Arbet-Engels · Chief Medical Officer · appointmenteff. 2025-10-01
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-06-16
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Altimmune, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.